Dr. Syed M. Raza, MD
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 129
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
AL license 4301088026 -
Pulmonary Disease Physician
MI license 4301088026 -
Sleep Medicine (Internal Medicine) Physician
MI license 4301088026
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beaumont Hospital - Dearborn Dearborn, MI
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 129
- Services billed
- 480
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 192 | 78 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 132 | 65 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 47 | 28 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 47 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 39 | 25 |
| Established patient office or other outpatient visit, 40-54 minutes | 17 | 16 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 14 | 14 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Riverview, MI | 31 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Riverview, MI | 15 |
| Fluticasone Propionate Other prescribers in Riverview, MI | 11 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Riverview, MI | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 11 payments worth $207 in total to this clinician.
| Insmed, Inc. | $36.16 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $26.19 |
| AbbVie Inc. | $24.34 |
| GlaxoSmithKline, LLC. | $22.75 |
| Electromed, Inc. | $18.10 |
| Genzyme Corporation | $17.49 |
| Axsome Therapeutics, Inc. | $16.96 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.88 |
| Food and Beverage | $207 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $341,759 in research payments for these studies, mostly to the institutions running them.
- A multicentre, randomized, double-blind, placebo-controlled, dose find
GlaxoSmithKline, LLC. - A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Verona Pharma, Inc. - Ph III OLE of Astegolimab in COPD
Genentech, Inc. - A randomized, double-blind, placebo-controlled, parallel-group, multic
GlaxoSmithKline, LLC. - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209 - A phase 3 placebocontrolled doubleblinded randomized study to evaluate the efficacy safety and tolerability of a clostridioides difficile vaccine in adults 65 years of age and older
Pfizer Inc. - Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Genzyme Corporation · Active, not recruiting · NCT05097287 - A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose…
AstraZeneca Pharmaceuticals LP - Ph IIb of Astegolimab in COPD
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.